Edwards Lifesciences Corporation

Edwards Lifesciences reports Q1 2006 $45.9 million net income, up from $31.2 million in 2005

Published in Cardiovascular Business Week, May 16th, 2006

Edwards Lifesciences Corporation (EW), a provider of products and technologies to treat advanced cardiovascular disease, reported net income for the quarter ended March 31, 2006 of $45.9 million, or 73 cents per diluted share, compared to net income of $31.2 million, or 50 cents per diluted share, for the same period in 2005.

First quarter net sales increased 3.1% to $256.7 million, compared to $249.1 million in the same quarter last year. Sales growth this quarter was negatively impacted by $8.8 million in foreign exchange (FX) and $5 million of sales from discontinued businesses.

For the first quarter, the company reported heart valve therapy sales...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2006-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry